Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

American Society of Clinical Oncology (ASCO) 2018 – Poster

Presentations

American Society of Clinical Oncology (ASCO) 2018 – Poster A PHASE 1 OPEN-LABEL, SAFETY, PHARMACOKINETIC, AND PRELIMINARY EFFICACY STUDY OF STRO-001, AN ANTI-CD74 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES,...

American Association for Cancer Research (AACR) 2018 – STRO-002 Poster

Presentations

American Association for Cancer Research (AACR) 2018 – STRO-002 Poster Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer STRO-002 AACR 2018 Poster...

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

Press Releases

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research – Phase 1 Trial Planned for Late 2018 – Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s...

American Association for Cancer Research (AACR) 2018 – STRO-002 Abstract

Presentations

American Association for Cancer Research (AACR) 2018 – STRO-002 Abstract Generation and Activity of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Folate receptor alpha (FolRa) is a glycosylphosphatidylinositol linked cell-surface...

Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Abstract

Presentations

Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Abstract Preclinical Activity and Safety of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.